Catheter ablation for atrial fibrillation in heart failure with reduced ejection fraction: a systematic review and meta-analysis of randomized controlled trials.
Anti-Arrhythmia Agents
/ adverse effects
Atrial Fibrillation
/ diagnosis
Catheter Ablation
/ adverse effects
Disease Progression
Heart Failure
/ diagnosis
Heart Rate
/ drug effects
Humans
Randomized Controlled Trials as Topic
Recovery of Function
Risk Factors
Stroke Volume
Treatment Outcome
Ventricular Function, Left
Atrial fibrillation
Catheter ablation
Heart failure
Journal
BMC cardiovascular disorders
ISSN: 1471-2261
Titre abrégé: BMC Cardiovasc Disord
Pays: England
ID NLM: 100968539
Informations de publication
Date de publication:
15 01 2019
15 01 2019
Historique:
received:
06
11
2018
accepted:
08
01
2019
entrez:
17
1
2019
pubmed:
17
1
2019
medline:
18
12
2019
Statut:
epublish
Résumé
Previous randomized controlled trials (RCT)s showed similar outcomes in patients with atrial fibrillation (AF) and heart failure with reduced ejection fraction (HFrEF) treated with anti-arrhythmic drugs (AAD) compared to rate control therapy. We sought to evaluate whether catheter ablation is superior to medical therapy in patients with AF and HFrEF. We searched electronic databases for all RCTs that compared catheter ablation and medical therapy (with or without use of AAD). We used random-effects models to summarize the studies. The primary end-point was all-cause mortality. Secondary outcomes included heart failure-related hospitalizations and change in left ventricular ejection fraction (LVEF). We retrieved and summarized 7 randomized controlled trials, enrolling 856 patients (429 in the catheter ablation arm and 427 in the medical therapy arm). Compared with medical therapy (including use of AAD), AF catheter ablation was associated with a significant reduction in mortality (risk ratio 0.50; 95% confidence interval [CI]: 0.34 to 0.74; P = 0.0005) and heart failure-related hospitalizations (risk ratio 0.56; 95% CI: 0.44 to 0.71; P < 0.0001). Furthermore, catheter ablation led to significant improvements in LVEF (weighted mean difference, 7.48; 95% CI: 3.71 to 11.26; P < 0.0001). Compared to medical therapy, including use of AAD, catheter ablation for AF was associated with a significant reduction in mortality and heart failure-related hospitalizations as well as an improvement in LVEF in patients with HFrEF. Larger trials are needed to confirm whether rhythm control with ablation is superior to rate control in patients with AF and heart failure.
Sections du résumé
BACKGROUND
Previous randomized controlled trials (RCT)s showed similar outcomes in patients with atrial fibrillation (AF) and heart failure with reduced ejection fraction (HFrEF) treated with anti-arrhythmic drugs (AAD) compared to rate control therapy. We sought to evaluate whether catheter ablation is superior to medical therapy in patients with AF and HFrEF.
METHODS
We searched electronic databases for all RCTs that compared catheter ablation and medical therapy (with or without use of AAD). We used random-effects models to summarize the studies. The primary end-point was all-cause mortality. Secondary outcomes included heart failure-related hospitalizations and change in left ventricular ejection fraction (LVEF).
RESULTS
We retrieved and summarized 7 randomized controlled trials, enrolling 856 patients (429 in the catheter ablation arm and 427 in the medical therapy arm). Compared with medical therapy (including use of AAD), AF catheter ablation was associated with a significant reduction in mortality (risk ratio 0.50; 95% confidence interval [CI]: 0.34 to 0.74; P = 0.0005) and heart failure-related hospitalizations (risk ratio 0.56; 95% CI: 0.44 to 0.71; P < 0.0001). Furthermore, catheter ablation led to significant improvements in LVEF (weighted mean difference, 7.48; 95% CI: 3.71 to 11.26; P < 0.0001).
CONCLUSIONS
Compared to medical therapy, including use of AAD, catheter ablation for AF was associated with a significant reduction in mortality and heart failure-related hospitalizations as well as an improvement in LVEF in patients with HFrEF. Larger trials are needed to confirm whether rhythm control with ablation is superior to rate control in patients with AF and heart failure.
Identifiants
pubmed: 30646857
doi: 10.1186/s12872-019-0998-2
pii: 10.1186/s12872-019-0998-2
pmc: PMC6332840
doi:
Substances chimiques
Anti-Arrhythmia Agents
0
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
18Références
JAMA. 2014 Feb 19;311(7):692-700
pubmed: 24549549
J Am Coll Cardiol. 1997 Mar 15;29(4):709-15
pubmed: 9091514
JACC Clin Electrophysiol. 2017 Dec 11;3(12):1425-1433
pubmed: 29759674
Circulation. 2009 May 12;119(18):2516-25
pubmed: 19433768
JACC Clin Electrophysiol. 2015 Jun 1;1(3):200-209
pubmed: 26258174
Heart Rhythm. 2008 Aug;5(8):1111-4
pubmed: 18675220
Eur Heart J. 2006 Jan;27(2):130-1
pubmed: 16299023
N Engl J Med. 2008 Jun 19;358(25):2667-77
pubmed: 18565859
Arch Intern Med. 2012 Jul 9;172(13):997-1004
pubmed: 22664954
J Am Coll Cardiol. 2014 Dec 2;64(21):e1-76
pubmed: 24685669
Circ Arrhythm Electrophysiol. 2014 Feb;7(1):31-8
pubmed: 24382410
J Am Coll Cardiol. 2004 Mar 17;43(6):1004-9
pubmed: 15028358
Eur Heart J. 2015 Dec 7;36(46):3250-7
pubmed: 26419625
JAMA. 2010 Jan 27;303(4):333-40
pubmed: 20103757
J Am Coll Cardiol. 2015 Aug 4;66(5):524-31
pubmed: 26227190
Circ Heart Fail. 2009 Nov;2(6):549-55
pubmed: 19919979
BMJ. 2016 Sep 06;354:i4482
pubmed: 27599725
Heart Fail Rev. 2017 Nov;22(6):641-655
pubmed: 28601914
Lancet. 2016 Sep 17;388(10050):1161-9
pubmed: 27515684
Eur Heart J. 2002 Jun;23(11):892-900
pubmed: 12042011
J Cardiovasc Electrophysiol. 2017 Jul;28(7):733-741
pubmed: 28419594
Circulation. 2008 Dec 9;118(24):2498-505
pubmed: 19029470
Heart. 2011 May;97(9):740-7
pubmed: 21051458
Eur Heart J. 2016 Oct 7;37(38):2893-2962
pubmed: 27567408
Lancet. 2000 Nov 25;356(9244):1789-94
pubmed: 11117910
J Am Coll Cardiol. 2012 Nov 6;60(19):1921-9
pubmed: 23062545
J Am Coll Cardiol. 2017 Oct 17;70(16):1949-1961
pubmed: 28855115
JAMA Cardiol. 2017 Jul 1;2(7):812-813
pubmed: 28423144
N Engl J Med. 1994 Sep 22;331(12):785-91
pubmed: 8065408
Heart Rhythm. 2017 Oct;14(10):e275-e444
pubmed: 28506916
Circulation. 2003 Apr 22;107(15):2011-5
pubmed: 12681998
J Am Coll Cardiol. 2002 May 1;39(9):1414-21
pubmed: 11985901
PLoS One. 2017 Oct 26;12(10):e0186856
pubmed: 29073191
J Am Coll Cardiol. 2011 Sep 27;58(14):1474-81
pubmed: 21939832
Europace. 2016 May;18(5):679-86
pubmed: 26843584
J Cardiovasc Electrophysiol. 2018 Jul;29(7):1049-1058
pubmed: 29630760
J Card Fail. 2011 Nov;17(11):964-70
pubmed: 22041335
Circulation. 2012 Jan 17;125(2):381-9
pubmed: 22249528
Eur Heart J. 2014 Sep 21;35(36):2454-9
pubmed: 25053659
N Engl J Med. 2004 Dec 2;351(23):2373-83
pubmed: 15575053
N Engl J Med. 2008 Oct 23;359(17):1778-85
pubmed: 18946063
JACC Clin Electrophysiol. 2016 Apr;2(2):170-180
pubmed: 29766867
Heart. 2009 Jun;95(11):924-30
pubmed: 19282313
J Am Coll Cardiol. 2013 May 7;61(18):1894-903
pubmed: 23500267
Circulation. 2001 Jul 17;104(3):292-6
pubmed: 11457747
Circulation. 2016 Apr 26;133(17):1637-44
pubmed: 27029350
N Engl J Med. 2018 Feb 01;378(5):417-427
pubmed: 29385358
N Engl J Med. 2002 Dec 5;347(23):1825-33
pubmed: 12466506
JACC Heart Fail. 2017 Aug;5(8):565-574
pubmed: 28711451
Eur Heart J. 2008 May;29(10):1290-5
pubmed: 18077441
Cardiovasc Res. 2002 May;54(2):347-60
pubmed: 12062340
Circulation. 2017 Apr 18;135(16):1547-1563
pubmed: 28416525
J Card Fail. 2008 May;14(4):320-6
pubmed: 18474345